LILRB1/ILT-2/CD85j

Antibody with azide: store at 2 to 8 degree C.<br>Antibody without azide: store at -20 to -80 degree C.<br>Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Leukocyte immunoglobulin-like receptors (LIRs) are members of the immunoglobulin superfamily of glycoproteins and are predominantly expressed by monocytes, B cells, dendritic cells, natural killer (NK) cells, peripheral blood leukocytes and tissues such as placenta, lung and liver. Immunoglobulin-like transcript 2 (ILT-2), also known as CD85 or MIR7, is a 650 amino acid glycoprotein that contains a 23 amino acid signal peptide, 4 extracellular C2-type IGSF domains and 4 intracellular ITIM motifs. ILT-2 can bind major histocompatability (MHC) class I molecules and inhibit cell termination by natural killer (NK) and T cells, and inhibit Ca2+ mobilization in myeloid cells triggered through the B cell antigen receptor and histocompatibility leukocyte antigens (HLA)-DR. ILT-2 contains four putative cytoplasmic tyrosine-based inhibitory motifs and upon tyrosine phosphorylation, associates with the tyrosine phosphatase SHP-1.

[LILRB1; LILRB1; ILT2; LIR1; MIR7; PIRB; CD85J; ILT-2; LIR-1; MIR-7; PIR-B; ILT2; LIR1; MIR7; LIR-1; Leukocyte immunoglobulin-like receptor 1; ILT-2; MIR-7]

[leukocyte immunoglobulin-like receptor subfamily B member 1 isoform 4; Leukocyte immunoglobulin-like receptor subfamily B member 1; leukocyte immunoglobulin-like receptor subfamily B member 1; leukocyte immunoglobulin like receptor B1; CD85 antigen-like family member J; Immunoglobulin-like transcript 2; ILT-2; Monocyte/macrophage immunoglobulin-like receptor 7]